Gables Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $849K | Buy |
3,374
+170
| +5% | +$36.6K | 0.31% | 70 |
|
|
2026
Q1 | $697K | Sell |
3,204
-100
| -3% | -$22.2K | 0.3% | 63 |
|
|
2025
Q4 | $755K | Hold |
3,304
| – | – | 0.32% | 65 |
|
|
2025
Q3 | $765K | Sell |
3,304
-200
| -6% | -$40.7K | 0.33% | 67 |
|
|
2025
Q2 | $650K | Sell |
3,504
-1,184
| -25% | -$220K | 0.31% | 67 |
|
|
2025
Q1 | $982K | Hold |
4,688
| – | – | 0.49% | 45 |
|
|
2024
Q4 | $833K | Buy |
4,688
+1,025
| +28% | +$188K | 0.4% | 52 |
|
|
2024
Q3 | $723K | Sell |
3,663
-1,025
| -22% | -$191K | 0.37% | 60 |
|
|
2024
Q2 | $804K | Buy |
4,688
+200
| +4% | +$33.1K | 0.42% | 49 |
|
|
2024
Q1 | $817K | Hold |
4,488
| – | – | 0.45% | 52 |
|
|
2023
Q4 | $696K | Hold |
4,488
| – | – | 0.43% | 54 |
|
|
2023
Q3 | $669K | Buy |
4,488
+70
| +2% | +$10.3K | 0.47% | 49 |
|
|
2023
Q2 | $595K | Buy |
4,418
+200
| +5% | +$29.3K | 0.39% | 58 |
|
|
2023
Q1 | $672K | Buy |
4,218
+46
| +1% | +$7.03K | 0.47% | 52 |
|
|
2022
Q4 | $674K | Hold |
4,172
| – | – | 0.49% | 49 |
|
|
2022
Q3 | $560K | Hold |
4,172
| – | – | 0.45% | 50 |
|
|
2022
Q2 | $639K | Hold |
4,172
| – | – | 0.48% | 49 |
|
|
2022
Q1 | $676K | Hold |
4,172
| – | – | 0.42% | 54 |
|
|
2021
Q4 | $565K | Hold |
4,172
| – | – | 0.34% | 69 |
|
|
2021
Q3 | $450K | Hold |
4,172
| – | – | 0.29% | 73 |
|
|
2021
Q2 | $470K | Sell |
4,172
-4,455
| -52% | -$502K | 0.32% | 72 |
|
|
2021
Q1 | $934K | Hold |
8,627
| – | – | 0.51% | 54 |
|
|
2020
Q4 | $924K | Hold |
8,627
| – | – | 0.54% | 51 |
|
|
2020
Q3 | $756K | Hold |
8,627
| – | – | 0.49% | 52 |
|
|
2020
Q2 | $847K | Buy |
8,627
+274
| +3% | +$24.1K | 0.59% | 48 |
|
|
2020
Q1 | $637K | Buy |
8,353
+1,488
| +22% | +$127K | 0.52% | 50 |
|
|
2019
Q4 | $607K | Buy |
6,865
+745
| +12% | +$61.8K | 0.41% | 69 |
|
|
2019
Q3 | $463K | Buy |
6,120
+3,915
| +178% | +$268K | 0.33% | 77 |
|
|
2019
Q2 | $160K | Hold |
2,205
| – | – | 0.13% | 116 |
|
|
2019
Q1 | $178K | Sell |
2,205
-235
| -10% | -$19.2K | 0.14% | 107 |
|
|
2018
Q4 | $225K | Sell |
2,440
-415
| -15% | -$36.5K | 0.2% | 95 |
|
|
2018
Q3 | $270K | Hold |
2,855
| – | – | 0.21% | 93 |
|
|
2018
Q2 | $269K | Hold |
2,855
| – | – | 0.22% | 86 |
|
|
2018
Q1 | $270K | Buy |
+2,855
| New | +$314K | 0.24% | 86 |
|
Other funds holding ABBV
Gables Capital Management's ABBV Position: Q2 2026 in Review
Gables Capital Management increased its AbbVie (ABBV) stake by 5.3% in Q2 2026, buying an estimated $36.6K and bringing the position to 3,374 shares worth $849K. The position accounts for 0.31% of the portfolio, ranked #70.
Gables Capital Management first reported a position in ABBV in Q1 2018 and has held it in 34 quarters since. The position peaked at $982K in Q1 2025. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Gables Capital Management held 3,374 shares of AbbVie worth $849K as of Q2 2026.
- Gables Capital Management bought 170 AbbVie shares in Q2 2026, an estimated $36.6K.
- AbbVie made up 0.31% of Gables Capital Management's portfolio in Q2 2026, its #70 holding.
- Gables Capital Management first reported a position in AbbVie in Q1 2018 and has held it in 34 quarters since.
- Gables Capital Management's AbbVie position peaked at $982K in Q1 2025.
- 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Gables Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.